Cargando…

Treatment of Shiga-Toxin Hus with Severe Neurologic Features with Eculizumab

Hemolytic Uremic Syndrome (HUS) is a constellation of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. Shiga toxin-producing Escherichia coli- (STEC-) mediated HUS is a common cause of acute renal failure in children and can rarely result in severe neurological complicat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Umscheid, Jacob H., Nevil, Collin, Vasudeva, Rhythm, Ali, Mohammed Farhan, Agasthya, Nisha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605924/ https://www.ncbi.nlm.nih.gov/pubmed/34812294 http://dx.doi.org/10.1155/2021/8053246

Ejemplares similares

Neonatal Appendicitis Presenting as Bilious Emesis and Septic Shock
por: Umscheid, Jacob H., et al.
Publicado: (2021)

Remission of aHUS neurological damage with eculizumab
por: Ávila, Ana, et al.
Publicado: (2015)

Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement
por: Pape, Lars, et al.
Publicado: (2016)

The Shiga Toxin Receptor Globotriaosylceramide as Therapeutic Target in Shiga Toxin E. coli Mediated HUS
por: Feitz, Wouter J. C., et al.
Publicado: (2021)

Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS)
por: Scheiring, Johanna, et al.
Publicado: (2008)

Severe Neurological Involvement in an Adult with Shiga Toxin-Producing Escherichia coli-Hemolytic Uremic Syndrome Treated with Eculizumab
por: Vanesse, Pauline, et al.
Publicado: (2023)

Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome
por: Walsh, Patrick R., et al.
Publicado: (2018)

Eculizumab and aHUS: Spotlight on Patient-Centered Care
por: Rafat, Cédric, et al.
Publicado: (2020)

Hemoconcentration and predictors in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS)
por: Loos, Sebastian, et al.
Publicado: (2021)

Can eculizumab be discontinued in aHUS?: Case report and review of the literature
por: Sahutoglu, Tuncay, et al.
Publicado: (2016)

Use of Eculizumab During Pregnancy in Kidney Transplant Recipients With Atypical HUS
por: Cheung, Chee Kay, et al.
Publicado: (2019)

Eculizumab Treatment for Postpartum HELLP Syndrome and aHUS—Case Report
por: Lokki, A. Inkeri, et al.
Publicado: (2020)

Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient
por: Bouwmeester, Romy N., et al.
Publicado: (2021)

Case Report: Neonatal Unexplained HUS Treated With Complement Inhibitor Eculizumab
por: Kelen, Dorottya, et al.
Publicado: (2021)

Prolonged Asthma Exacerbation as an Initial Presentation in Hereditary Hemorrhagic Telangiectasia
por: Umscheid, Jacob, et al.
Publicado: (2021)

A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
por: Rathbone, John, et al.
Publicado: (2013)

Clinical Relapses of Atypical HUS on Eculizumab: Clinical Gap for Monitoring and Individualised Therapy
por: Teoh, Chia Wei, et al.
Publicado: (2018)

Inhibition of terminal complement activation in severe Shiga toxin-associated HUS – perfect example for a fast track from bench to bedside
por: Orth-Höller, Dorothea, et al.
Publicado: (2011)

Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD
por: McBride, Helen J., et al.
Publicado: (2023)

Case Report: Atypical HUS Presenting With Acute Rhabdomyolysis Highlights the Need for Individualized Eculizumab Dosing
por: Benoit, Stefanie W., et al.
Publicado: (2022)

An Atypical Case of Shiga Toxin Producing-Escherichia Coli Hemolytic and Uremic Syndrome (STEC-HUS) in a Lung Transplant Recipient
por: Manière, Louis, et al.
Publicado: (2019)

Shiga toxin-producing Escherichia coli haemolytic uraemic syndrome (STEC-HUS): diagnosis, surveillance and public-health management in England
por: Jenkins, Claire, et al.
Publicado: (2020)

Case report: Eculizumab plus obinutuzumab induction in a deceased donor kidney transplant recipient with DEAP-HUS
por: Favi, Evaldo, et al.
Publicado: (2022)

Case report: Short-term eculizumab use in atypical HUS associated with Lemierre's syndrome and post-infectious glomerulonephritis
por: Sadiq, Sanober, et al.
Publicado: (2023)

Shiga Toxin Mediated Neurologic Changes in Murine Model of Disease
por: Pradhan, Suman, et al.
Publicado: (2016)

Development of camelid single chain antibodies against Shiga toxin type 2 (Stx2) with therapeutic potential against Hemolytic Uremic Syndrome (HUS)
por: Mejías, Maria P., et al.
Publicado: (2016)

Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report
por: Ohanian, Maro, et al.
Publicado: (2011)

Low C3 Serum Levels Predict Severe Forms of STEC-HUS With Neurologic Involvement
por: Netti, Giuseppe Stefano, et al.
Publicado: (2020)

Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study
por: Bouwmeester, Romy N., et al.
Publicado: (2022)

Complete remission of thrombotic microangiopathy after treatment with eculizumab in a patient with non-Shiga toxin-associated bacterial enteritis: A case report
por: Omura, Taku, et al.
Publicado: (2016)

Comparative Genomics to Delineate Pathogenic Potential in Non-O157 Shiga Toxin-Producing Escherichia coli (STEC) from Patients with and without Haemolytic Uremic Syndrome (HUS) in Norway
por: Haugum, Kjersti, et al.
Publicado: (2014)

Ongoing haemolytic uraemic syndrome (HUS) outbreak caused by sorbitol-fermenting (SF) Shiga toxin-producing Escherichia coli (STEC) O157, Germany, December 2016 to May 2017
por: Vygen-Bonnet, Sabine, et al.
Publicado: (2017)

Roles of Shiga Toxins in Immunopathology
por: Lee, Moo-Seung, et al.
Publicado: (2019)

Protection against Shiga Toxins
por: Kavaliauskiene, Simona, et al.
Publicado: (2017)

Shiga Toxins as Antitumor Tools
por: Robert, Aude, et al.
Publicado: (2021)

Predictors of Length of Stay and Cost of Hospitalization of Neonatal Abstinence Syndrome in the United States
por: Bhatt, Parth, et al.
Publicado: (2021)

Phylogenetic analysis of Shiga toxin 1 and Shiga toxin 2 genes associated with disease outbreaks
por: Lee, James E, et al.
Publicado: (2007)

Purification and Characterization of Shiga Toxin 2f, an Immunologically Unrelated Subtype of Shiga Toxin 2
por: Skinner, Craig, et al.
Publicado: (2013)

Do the A Subunits Contribute to the Differences in the Toxicity of Shiga Toxin 1 and Shiga Toxin 2?
por: Basu, Debaleena, et al.
Publicado: (2015)

Characterization of Shiga Toxin Subtypes and Virulence Genes in Porcine Shiga Toxin-Producing Escherichia coli
por: Baranzoni, Gian Marco, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dufumqc98udmhrvjm5m106vo4t